Chugai Pharm. (4519, Neutral): Looking beyond 1H results: Actemra facing new competition; ACE-910 and atezolizumab to drive growth, but valuations appear to discount it
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok